Clinical trial
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of…
NCT00481845 · Stanford University, Other · Terminated
Key facts
| NCT number | NCT00481845 |
|---|---|
| Title | Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer |
| Official title | Randomized Phase 2 Trial of Anastrozole Combined With Novel Agent ZD6474 in the Neoadjuvant Treatment of Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer |
| Lead sponsor | Stanford University, Other |
| Collaborators | AstraZeneca Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Vandetanib, Anastrozole |
| Enrollment | 1 |
| Start date | Jan 1, 2008 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jun 4, 2007 |
| Last update posted | Feb 7, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: